A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

Inclusion Criteria: * Diagnosed as CRSwNP and treated with systemic glucocorticoid within 2 years before screening; and/or those who had undergone surgery for nasal polyps before screening. * An endoscopic bilateral NPS at screening/lead-in period and the baseline period of at least 5 out of a maximum score of 8 (with a minimum socre of 2 in each nasal cavity). * Nasal congestion/blockade/obstruction with moderate or severe symptom severity at at screening period (score 2 or 3 ) . * Willing to sign an informed consent, able to comply with clinic visits and study-related procedures as per protocol. Exclusion Criteria: * Biologic therapy within 5 half-lives or within 10 weeks before baseline. * Anti-IL-4Rα antibody before screening. * An experimental drug within 5 half-lives or 1 months before baseline. * Systemic immunosuppressant to treat inflammatory disease or autoimmune disease within 2 months or 5 half-lives before baseline. * Initiation of allergen immunotherapy within 3 months before screening. * Participants receiving leukotriene antagonist/modifier before screening unless on continous treatment for at least 30 days. * Participants with FEV1 50% or less of predicted normal were excluded. * Participants who have undergone any intranasal and/or sinus surgery within 6 months before screening. * Acute sinusitis or upper respiratory infection within a defined time period before screening. * A nasal cavity tumor (malignant or benign). * Evidence of fungal rhinosinusitis. * Presence of another diagnosis associated with nasal polyps (i.e., eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young's syndrome, cystic fibrosis). * Rhinitis medicamentosa. * Nasal septal deviation occluding at least one nostril. * Antrochoanal polyps. * Pregnant or lactating woman.